"IDX316 retained activity against common mutations in NS3 and exhibited enhanced activity when combined with standard-of-care agents or other Idenix compounds in development (IDX184 and IDX375). Favorable PK profiles in rodent and non-human primate species suggest the potential for once- or twice-daily dosing in humans (half-life of 4.0-5.2 h; bioavailability of ~20%)."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.